1
|
Tong Z, Liu X, Tao Y, Feng P, Luan F, Jie X, Xie Z, Pu F, Xu Z, Wang P. Enhancement of dissolution and oral bioavailability by adjusting microenvironment pH in crocetin ternary solid dispersions: Optimization, characterization, in vitro evaluation, and pharmacokinetics. Drug Deliv Transl Res 2023:10.1007/s13346-023-01497-3. [PMID: 38117406 DOI: 10.1007/s13346-023-01497-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/11/2023] [Indexed: 12/21/2023]
Abstract
The most promising active ingredient of Crocus sativus L., crocetin (CCT), has been demonstrated to possess many biological activities. However, only a few studies have been conducted on CCT formulation, especially in oral formulation, mainly due to its insolubility in water, which limits its application for oral administration. This article reports an equilibrium saturation solubility and single-pass intestinal perfusion studies conducted to classify the biopharmaceutics classification system (BCS) of CCT. To enhance in vitro dissolution and in vivo oral bioavailability, ternary solid dispersions of CCT (CCT-SDs) with soluplus (SOL) as hydrophilic carrier and meglumine (MEG) as alkalizer were optimized using response surface methodology (RSM) with central composite design (CCD) experiments. Four different preparation methods were evaluated using the optimal formulation, including solvent evaporation, ball milling, spray drying, and freeze-drying. Prepared formulations were characterized by TG-DSC, FTIR, X-RPD, and SEM; the pharmacokinetic studies were performed in rats after oral administration. The cumulative dissolution rate of CCT-SDs containing SOL and MEG prepared by the ball milling method was 97.1% at 15 min and remained at 95.6% at 480 min, which was significantly higher than that of untreated CCT. The lower crystallinity, smaller particle size, and higher microenvironment pH (pHM) were observed in CCT-SDs prepared by the ball milling method. In vivo absorption of CCT-SDs (Cmax = 52.789 ± 12.441 μg/mL and AUC0-12 = 191.748 ± 35.043 μg/mL·h) was greater than untreated CCT (Cmax = 5.918 ± 1.388 μg/mL and AUC0-12 = 44.309 ± 7.264 μg/mL·h). In conclusion, the current study provides ternary solid dispersion formulation of CCT to increase the in vitro dissolution and in vivo bioavailability, which will benefit the commercial production and future clinical applications of CCT.
Collapse
Affiliation(s)
- Zheren Tong
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Xianyin Liu
- College of Pharmaceutical Sciences, Jiangxi Medical College, Shangrao, 334000, China
| | - Yi Tao
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Peishi Feng
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Fujia Luan
- College of Pharmaceutical Sciences, Jiangxi Medical College, Shangrao, 334000, China
| | - Xiaolu Jie
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Zhangfu Xie
- Zhejiang Suichang Liming Pharmaceutical Co., LTD, Suichang, 323300, China
| | - Faxiang Pu
- Zhejiang Suichang Liming Pharmaceutical Co., LTD, Suichang, 323300, China
| | - Zijin Xu
- College of Pharmaceutical Sciences, Jiangxi Medical College, Shangrao, 334000, China.
| | - Ping Wang
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, 310014, China.
| |
Collapse
|
2
|
Sohn JS, Choi JS. Development and evaluation of febuxostat solid dispersion through screening method. Saudi Pharm J 2023; 31:101724. [PMID: 37559865 PMCID: PMC10406859 DOI: 10.1016/j.jsps.2023.101724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 07/24/2023] [Indexed: 08/11/2023] Open
Abstract
Febuxostat (Febux) is a BCS II drug and has a very low solubility. In order to overcome this shortcoming, the purpose of study is to increase the in vitro dissolution (%) and drug release (%) of Febux by using a screening method. The Febux-SD formulation was prepared by screening solubilizers, pH agents, and carriers using with a solvent evaporation method. The novel Febux SD formulation was successfully developed. The dissolution (%) of Febux of optimal formulation (SD3) was higher than that of Feburic® tab in pH 1.2, distilled water (DW), and pH 6.8 buffer by 6.3-, 2.6-, and 1.1-fold, respectively, at 60 min. The in vitro drug release (%) and permeability (μg/cm2) of SD3 formulation were improved compared to those of Feburic® tab in the pH shifting method and PBS (7.4), respectively. The SD3 formulation was well maintained the stability for 6 months, and that of physicochemical properties were altered. In conclusion, the Febux solubilization study with meglumine was first attempted and successfully performed. Through the improved dissolution (%) of Febux, high bioavailability of SD3 formulation is expected in animal and human studies.
Collapse
Affiliation(s)
- Jeong Sun Sohn
- College of General Education, Chosun University, Gwangju 61452, Republic of Korea
| | - Jin-Seok Choi
- Department of Medical Management, Chodang University, 380 Muan-ro, Muan-eup, Muan-gun, Jeollanam-do 58530, Republic of Korea
| |
Collapse
|
3
|
Tian YM, Hofmann E, Silva W, Pu X, Touraud D, Gschwind RM, Kunz W, König B. Enforced Electronic-Donor-Acceptor Complex Formation in Water for Photochemical Cross-Coupling. Angew Chem Int Ed Engl 2023; 62:e202218775. [PMID: 36735337 DOI: 10.1002/anie.202218775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/02/2023] [Accepted: 02/03/2023] [Indexed: 02/04/2023]
Abstract
The amino alcohol meglumine solubilizes organic compounds in water and enforces the formation of electron donor acceptor (EDA) complexes of haloarenes with indoles, anilines, anisoles or thiols, which are not observed in organic solvents. UV-A photoinduced electron transfer within the EDA complexes induces the mesolytic cleavage of the halide ion and radical recombination of the arenes leading, after rearomatization and proton loss to C-C or C-S coupling products. Depending on the substitution pattern selective and unique cross-couplings are observed. UV and NMR measurements reveal the importance of the assembly for the photoinduced reaction. Enforced EDA aggregate formation in water allows new activation modes for organic photochemical synthesis.
Collapse
Affiliation(s)
- Ya-Ming Tian
- Faculty of Chemistry and Pharmacy, Institute of Organic Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Evamaria Hofmann
- Faculty of Chemistry and Pharmacy, Institute of Physical and Theoretical Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Wagner Silva
- Faculty of Chemistry and Pharmacy, Institute of Organic Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Xiang Pu
- Faculty of Chemistry and Pharmacy, Institute of Organic Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Didier Touraud
- Faculty of Chemistry and Pharmacy, Institute of Physical and Theoretical Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Ruth M Gschwind
- Faculty of Chemistry and Pharmacy, Institute of Organic Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Werner Kunz
- Faculty of Chemistry and Pharmacy, Institute of Physical and Theoretical Chemistry, University Regensburg, 93040, Regensburg, Germany
| | - Burkhard König
- Faculty of Chemistry and Pharmacy, Institute of Organic Chemistry, University Regensburg, 93040, Regensburg, Germany
| |
Collapse
|
4
|
Löscher W, Trinka E. The potential of intravenous topiramate for the treatment of status epilepticus. Epilepsy Behav 2023; 138:109032. [PMID: 36528009 DOI: 10.1016/j.yebeh.2022.109032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 11/28/2022] [Accepted: 11/28/2022] [Indexed: 12/23/2022]
Abstract
There is considerable clinical evidence that topiramate (TPM) has a high potential in the treatment of refractory and super-refractory status epilepticus (RSE, SRSE). Because TPM is only approved for oral administration, it is applied as suspension via a nasogastric tube for SE treatment. However, this route of administration is impractical in an emergency setting and leads to variable absorption with unpredictable plasma levels and time to peak concentration. Thus, the development of an intravenous (i.v.) solution for TPM is highly desirable. Here we present data on two parenteral formulations of TPM that are currently being developed. One of these solutions is using sulfobutylether-β-cyclodextrin (SBE-β-CD; Captisol®) as an excipient. A 1% solution of TPM in 10% Captisol® has been reported to be well tolerated in safety studies in healthy volunteers and patients with epilepsy or migraine, but efficacy data are not available. The other solution uses the FDA- and EMA-approved excipient amino sugar meglumine. Meglumine is much more effective to dissolve TPM in water than Captisol®. A 1% solution of TPM can be achieved with 0.5-1% of meglumine. While the use of Captisol®-containing solutions is restricted in children and patients with renal impairment, such restrictions do not apply to meglumine. Recently, first-in-human data were reported for a meglumine-based solution of TPM, indicating safety and efficacy when used as a replacement for oral administration in a woman with epilepsy. Based on the multiple mechanisms of action of TPM that directly target the molecular neuronal alterations that are thought to underlie the loss of efficacy of benzodiazepines and other anti-seizure medications during prolonged SE and its rapid brain penetration after i.v. administration, we suggest that parenteral (i.v.) TPM is ideally suited for the treatment of RSE and SRSE. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.
Collapse
Affiliation(s)
- Wolfgang Löscher
- Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, 30559 Hannover, Germany; Center for Systems Neuroscience, 30559 Hannover, Germany.
| | - Eugen Trinka
- Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria; Center for Cognitive Neuroscience, Salzburg, Austria
| |
Collapse
|
5
|
Li H, Wang J, Xu Q, Tian S, Yang W. Design and Evaluation of Glimepiride Hydrogel for Transdermal Delivery. Drug Dev Ind Pharm 2022; 48:397-405. [PMID: 36048002 DOI: 10.1080/03639045.2022.2120493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The solubility of glimepiride (GM) was improved from 1.6 μg/mL to 22.0 mg/mL when GM and meglumine (MU) complexes were prepared. Therefore, transdermal hydrogels of GM Carbopol (GM-CP) and GM hydroxypropyl methylcellulose pullulan (GM-HPMC-Pu) were prepared successfully utilizing the improved drug solubility by GM-MU. Based on single factor experiment and response surface methodology, two kinds of hydrogel formulations were optimized by drug release studies in vitro. The optimized GM-CP hydrogel was composed of GM, the mixture of azone and oleic acid (1:1, 2.6%, v/v) and carbopol 940 (1%, w/v). The GM-HPMC-Pu hydrogel was developed using GM, HPMC (3.5%, w/v), Pu (1.5%, w/v), glycerol (5%, v/v), azone (2.9%, v/v) and oleic acid (2.6%, v/v). The study of hydrogels in vivo was performed using rabbits. The results indicated that the drug could sustain release from GM-CP or GM-HPMC-Pu hydrogel and maintain the high plasma concentration for 48 h. Compared with commercial GM tablet, the relative bioavailability of GM-CP and GM-HPMC-Pu hydrogel reached up 48% and 133%, respectively. Moreover, the drug release in vitro could well predict its absorption in vivo. There was a good correlation (R2 ≥0.966) in GM hydrogel between the drug release in vitro and transdermal absorption in vivo. Therefore, a novel GM hydrogel dosage form may be considered to design.
Collapse
Affiliation(s)
- Haiying Li
- College of Pharmaceutical Sciences & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, PR China
| | - Jiajia Wang
- College of Pharmaceutical Sciences & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, PR China
| | - Qianru Xu
- College of Pharmaceutical Sciences & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, PR China
| | - Shuya Tian
- College of Pharmaceutical Sciences & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, PR China
| | - Wenzhi Yang
- College of Pharmaceutical Sciences & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, PR China
| |
Collapse
|
6
|
He X, Wei Y, Wang S, Zhang J, Gao Y, Qian S, Pang Z, Heng W. Improved Pharmaceutical Properties of Honokiol via Salification with Meglumine: an Exception to Oft-quoted ∆pK a Rule. Pharm Res 2022. [PMID: 35836038 DOI: 10.1007/s11095-022-03335-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 07/05/2022] [Indexed: 10/17/2022]
Abstract
Honokiol (HK), a BCS class II drug with a wide range of pharmacological activities, has poor solubility and low oral bioavailability, severely limiting its clinical application. In the current study, incorporating a water-soluble meglumine (MEG) into the crystal lattice of HK molecule was performed to improve its physicochemical properties. The binary mixture of HK and MEG was obtained by anti-solvent method and characterized by TGA, DSC, FTIR, and PXRD. The SCXRD analysis showed that two HK- molecules and two MEG+ molecules were coupled in each unit cell via the ionic interaction along with intermolecular hydrogen bonds, suggesting the formation of a salt, which was further confirmed by the XPS measurements. However, the ∆pKa value between HK and MEG was found to be less than 1, which did not follow the oft-quoted ∆pKa rule for salt formation. After salification with MEG, the solubility and dissolution rate of HK exhibited 3.50 and 25.33 times improvement than crystalline HK, respectively. Simultaneously, the powder flowability, tabletability and stability of HK-MEG salt was also significantly enhanced, and the salt was not more hygroscopic, and that salt formation did not compromise processability in that regard. Further, in vivo pharmacokinetic study showed that Cmax and AUC0-t of HK-MEG salt were enhanced by 2.92-fold and 2.01-fold compared to those of HK, respectively, indicating a considerable improvement in HK oral bioavailability.
Collapse
|
7
|
Sridharan K, Sivaramakrishnan G. Comparative assessment of interventions for treating cutaneous leishmaniasis: A network meta-analysis of randomized clinical trials. Acta Trop 2021; 220:105944. [PMID: 33957088 DOI: 10.1016/j.actatropica.2021.105944] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 03/28/2021] [Accepted: 04/26/2021] [Indexed: 01/19/2023]
Abstract
INTRODUCTION Various interventions including laser therapy, heat therapy, and several drugs have been trialed in patients with cutaneous leishmaniasis. Due to the lack of an evidence-based comparison of all these interventions, we carried out the present network meta-analysis. METHODS Electronic databases were searched for randomized clinical trials evaluating the efficacy and safety of any interventions in patients with cutaneous leishmaniasis. The proportion of patients with complete cure was the primary outcome. The proportion of lesions cured at the end of treatment, the proportion of lesions with minimal/no response to treatment, and proportion of wounds with minimal/no change were the secondary outcomes. Random-effects modeling was used for generating pooled estimates. Rankogram plot was used for identifying the 'best intervention'. For interventions containing a combination of treatments, backslash (/) has been used for depicting the same. RESULTS One-hundred and thirty-one studies were included. Intralesional meglumine, topical paromomycin/gentamicin, topical paromomycin, parenteral sodium stibogluconate, topical honey/intralesional meglumine, topical liposomal amphotericin B, oral zinc sulphate, oral miltefosine, parenteral meglumine, heat therapy, topical liposomal azithromycin, intralesional meglumine/silver dressing, intralesional sodium stibogluconate, parenteral meglumine/intralesional meglumine, oral allopurinol/parenteral meglumine, topical trichloroacetic acid/heat therapy, oral zinc sulphate/oral ketoconazole, topical imiquimod/cryotherapy, intralesional meglumine/cryotherapy, topical herbal extract of Z-HE, parenteral pentamidine, topical trichloroacetic acid/intralesional meglumine, carbon-dioxide laser, topical recombinant granulocyte-macrophage colony-stimulating factor/parenteral meglumine, intralesional dapsone, carbon-dioxide laser/intralesional meglumine, moist wet dressing with sodium hypochlorite, parenteral sodium stibogluconate/intralesional recombinant granulocyte-macrophage colony-stimulating factor, oral dapsone, intralesional sodium stibogluconate/oral ketoconazole, intralesional sodium stibogluconate/parenteral sodium stibogluconate and electrocautery/moist wet dressing with sodium hypochlorite were observed with significantly greater proportion of patients with complete cure compared to placebo/untreated controls. Rankogram analysis revealed that parenteral pentamidine has the highest statistical probability of being the best in the pool. CONCLUSION We observed several interventions to be effective for treating cutaneous leishmaniasis. However, greater caution is required in interpreting the results as the estimates are likely to change with the advent of results from future studies.
Collapse
Affiliation(s)
- Kannan Sridharan
- Department of Pharmacology & Therapeutics, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
| | | |
Collapse
|
8
|
Li H, Ma L, Li X, Cui X, Yang W, Shen S, Chen M. A simple and effective method to improve bioavailability of glimepiride by utilizing hydrotropy technique. Eur J Pharm Sci 2015; 77:154-60. [PMID: 26093052 DOI: 10.1016/j.ejps.2015.06.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2015] [Revised: 06/15/2015] [Accepted: 06/16/2015] [Indexed: 11/27/2022]
Abstract
The purpose of this study was to improve the solubility and bioavailability of glimepiride (GLMP) by utilizing hydrotropy technique. Meglumine (MU) as a hydrotrope could form the stable complex with glimepiride. The optimal glimepiride and meglumine (GLMP-MU) complex powder was obtained by using lyophilization. GLMP-MU powder was characterized by Fourier transform infrared spectroscopy (FT IR), X-ray powder diffraction (XRD) and differential scanning calorimetry (DSC). The formation of hydrogen bond between glimepiride and meglumine was confirmed by FT IR. The XRD studies indicated the amorphous state of glimepiride was appeared in the GLMP-MU. The DSC results were further confirmed GLMP-MU complex was prepared successfully. Moreover, the in vitro drug release rate of GLMP-MU powder was dramatically faster than that of glimepiride. Meanwhile, the AUC of GLMP-MU solution at an i.g./or i.v. dose of 5mg/kg in rat was significantly higher than that of the glimepiride suspensions. Together our results showed that hydrotropy technique was a simple and effective method to increase the solubility of glimepiride.
Collapse
Affiliation(s)
- Haiying Li
- College of Pharmacy & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China
| | - Lilan Ma
- College of Pharmacy & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China
| | - Xiaxia Li
- College of Pharmacy & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China
| | - Xin Cui
- College of Pharmacy & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China
| | - Wenzhi Yang
- College of Pharmacy & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China.
| | - Shigang Shen
- College of Pharmacy & Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Hebei University, Baoding 071002, China
| | - Mingmao Chen
- Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou 350108, China.
| |
Collapse
|